Supports investigator-initiated clinical trials for neurological disorders, from early exploratory studies to Phase 3 confirmatory and comparative effectiveness trials.
NIH plans a milestone-driven award supporting planning and early to definitive clinical trials across biomedical and other interventions for up to 7 years; applications are not yet being accepted.
NHLBI plans to fund single-site clinical trials (R61/R33) testing therapeutic, behavioral, or prevention strategies, encouraging innovative designs.
Funding support available to study and prove effectiveness of potential neurotherapeutic agents for neurological disorders towards further development.
Encourages translational activities and small clinical studies for neural devices to address disorders affecting the nervous system; includes prototype development, safety testing, and clinical validation.
Funding for early testing of new drug or device treatments for mental disorders to understand mechanisms and assess clinical effects.